RxDoctor Payments Data

Okezie Aguoru, MD

Family Medicine · Houston, TXNPI 1063677672

Payments from drug & device makers

$4,025in general payments, 2019–2025

Across 197 payments — averaging $20.43 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$938
  • GSK$853
  • Boehringer Ingelheim$456
  • Novo Nordisk$442
  • Pfizer$216
  • Lilly USA, LLC$147
  • plus $974 from 15 others

What the payments were for

  • Food & beverage$3,96599%
  • Gifts$591%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$4,025 in reported general payments places this provider in the 80th percentile of 8,760 family medicine providers in Texas.

See all family medicine providers in Texas

Medicare billing

Part B allowed, 2024
$40,752
Medicare patients
135
Services billed
581

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide59$61,975
MounjaroTirzepatide50$56,599
Trelegy ElliptaFluticasone/Umeclidin/Vilanter80$50,562
EliquisApixaban33$38,539
JardianceEmpagliflozin46$37,779
Trijardy XrEmpaglifloz/Linaglip/Metformin25$24,370
FarxigaDapagliflozin Propanediol24$23,962
JanuviaSitagliptin Phosphate22$22,866
Xigduo XrDapaglifloz Propaned/Metformin12$14,007
XareltoRivaroxaban16$11,839
Advair HfaFluticasone Propion/Salmeterol13$5,649
Albuterol Sulfate HfaAlbuterol Sulfate134$2,672
Atorvastatin Calcium221$2,362
Tadalafil15$1,938
Omeprazole98$1,885

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimJardiance, Trijardy Xr$456$62,14971 claims
Novo NordiskOzempic$442$61,97559 claims
Lilly USA, LLCMounjaro$147$56,59950 claims
GSKTrelegy Ellipta$853$50,56280 claims
PfizerEliquis$216$38,53933 claims
AstraZenecaFarxiga$938$23,96224 claims
Johnson & JohnsonXarelto$17$11,83916 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 8,760 family medicine providers in Texas.

Other family medicine in Houston

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →